Topics in Cardiology, Preventive Cardiology, Cardiometabolic Disease, Preventive Endocrinology, and Lipidology is organized by Continuing Education, Inc and will be held from Dec 01 - 08, 2018 at 7-Night Western Caribbean Cruise Conference Round-trip Miami, Miami, Florida, United States of America.
The target audience for this medical event is Family Physicians, Physician Assistants, Nurses, Nurse Practitioners. This CME Conference has been approved for a maximum of 14 AMA PRA Category 1 Credits.
Management of Hyperlipidemia: A cardiologists perspective
• Review the evidence to support the use of statins for primary and secondary prevention.
• Review the evidence to support the elimination of non-statin therapy from lipid treatment guidelines.
• Review of current national and international practice guidelines.
Cardiac Risk Assessment: Risk calculators and incorporating cardiac imaging.
• Appreciate the value and limitations of cardiovascular risk calculators.
• Understand the utility and role of non-invasive arterial imaging modalities.
Cardiac coronary artery CT imaging in the diagnosis of chest pain.
• Protocols for coronary artery CT imaging; benefits, risks and value?
• Identify appropriate candidates with chest pain syndromes for coronary artery CT imaging.
The role of PCSK9 inhibitors in the treatment of atherosclerotic cardiovascular disease.
• Understand the role of PCSK9 inhibitor therapy in management of dyslipidemia.
• Review of clinical trials evaluating the clinical benefits of injectable PCSK9 treatment.
Statin Intolerance/Resistance: Is the problem the patient or the drug?
• Understand the physiologic basis and incidence of statin intolerance.
• Review of treatment options for patients who are statin intolerant or resistant.
Management of Symptomatic Stable CAD: Stents for everybody?
• Appreciate in which patients are percutaneous coronary intervention and surgical revascularization are useful.
• Review novel medical therapies for CAD.
Plaque reversal: myth or reality?
• Is the development of atherosclerotic plaque an inevitable consequence of untreated cardiovascular risk factors?
• What is the evidence for interventions that claim to prevent plaque progression or promote plaque regression?
Additional details will be posted as soon as they are available.
|Registration Type||End Date||Price|
|Physicians, Attorneys, Psychologists, Doctors of Pharmacy & Dentists Fee||30 Nov,2018||USD 895.00|
|Physician Assistants, Nurse Practitioners Fee||30 Nov,2018||USD 695.00|
|Nurses, Residents, Students & Others Fee||30 Nov,2018||USD 495.00|